Peritoneal clearance of homocysteine with icodextrin or standard glucose solution exchange

Nephrology

Volumn 10, Issue 6, 2005, Pages 571-575

  Czupryniak, Aneta ^a   Nowicki, Michal ^a,b   Chwatko, Grazyna ^a   Jander, Anna ^a   Bald, Edward ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

High performance liquid chromatography; Homocysteine; Icodextrin; Peritoneal dialysis

Indexed keywords

GLUCOSE; HOMOCYSTEINE; ICODEXTRIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIALYSATE LEVEL; DRUG EFFECT; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADULT; FEMALE; GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HOMOCYSTEINE; HUMANS; MALE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM;

EID: 29144517307     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00483.x     Document Type: Article

References (31)

1. Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med. 1999; 159: 1077-80.
2. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-41.
3. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage patients on dialysis: A case-control study. Atherosclerosis 1995; 114: 93-103.
4. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol. 1999; 10: 891-900.
5. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors. Clin. Nephrol. 2002; 57: 327-35.
6. Moustapha A, Gupta A, Robinson K et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis patients. Kidney Int. 1999; 55: 1470-75.
7. Bostom AG, Shemin D, Lapane KL et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1995; 123: 193-202.
8. Vychytil A, Fodinger M, Wolfl G et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int. 1998; 53: 1775-82.
9. Janssen MJ, van Guldener C, de Jong GM, van den Berg M, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996; 22: 110-14.
10. House A, Wells G, Donnelly J et al. Randomised trial of high-flux vs low-flux hemodialysis: effects on homocysteine and lipids. Nephrol. Dial. Transplant. 2000; 15: 1029-34.
11. Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 2002; 61: 705-16.
12. Ducloux D, Heuze-Lecornu L, Gibey R, Bresson-Vautrin C, Vautrin P, Chalopin JM. Dialysis adequacy and homocyst(e)ine concentrations in peritoneal dialysis patients. Nephrol. Dial. Transplant. 1999; 14: 728-31.
13. Vychytil A, Fodinger M, Papagiannopoulos M, Wolfl G, Horl WH, Sunder-Plassmann G. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int. 1999; 55: 2054-61.
14. De Vecchi AF, Catena FB, Accinni R, Patrosso C. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis. Kidney Int. 1999; 56: 1604-5.
15. Johnson DW, Kay TD, Vesey DA, Isbel N, Campbell SB, Hawley CM. Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit. Dial. Int. 2000; 20: 766-72.
16. Hirose S, Kono R, Mitarai T, Isoda K, Kim S, Shimoyama H. Hyperhomocysteinemia in CAPD patients: Peritoneal transport of total homocysteine at peritoneal equilibration test and daily elimination of total homocysteine. Nippon Jinzo Gakkai Shi 1999; 41: 778-86.
17. Feriani M, Catizone L, Fracasso A. Peritoneal dialysis solutions and systems. In: Gokal R, Khanna R, Krediet RT, Nolph K, eds. Textbook of Peritoneal Dialysis. Dordrecht: Kluwer. Academic Publishers, Amsterdam, the Netherlands, 2000; 253-305.
18. Siamopoulos KC. Severe asymptomatic hyperglycemia in non-diabetic CAPD patients. Perit. Dial. Int. 1992; 12: 72-3.
19. De Vries AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis. Perit. Dial. Int. 2001; 21: S9-S18.
20. Burkart J. Metabolic consequences of peritoneal dialysis. Semin. Dial. 2004; 17: 498-504.
21. Honda K, Nitta K, Horita S et al. Accumulation of advanced glycation end-products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol. Dial. Transplant. 1999; 14: 1541-9.
22. Mistry CD, Gokal R. Icodextrin in peritoneal dialysis: Early development and clinical use. Perit. Dial. Int. 1994; 14: S13-S21.
23. Peers E, Gokal R. Icodextrin: Overview and clinical experience. Perit. Dial. Int. 1997; 17: 22-6.
24. Posthuma N, ter Wee PM, Verbrugh HA et al. Icodextrin instead of glucose during the daytime in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol. Dial. Transplant. 1997; 12: 550-53.
25. Finkelstein F, Healy H, Abu-Alfa A et al. Superiority of icodextrin compared with 4.25% glucose in optimizing peritoneal ultrafiltration. J. Am. Soc. Nephrol. 2005; 16: 546-54.
26. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J. Intern. Med. 1999; 246: 425-54.
27. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 1916; 17: 863-71.
28. Bald E, Chwatko GG, Glowacki R, Kuœmierek K. Analysis of plasma thiols by high performance liquid chromatography with ultraviolet detection. Chromatogr. A 2004; 1032: 109-15.
29. Bald EG, Gowacki R. 2-Chloro-1 -methylquinolinium tetrafluoroborate as an effective and thiol specific UV-tagging reagent for liquid chromatography. J. Liq. Chrom. Rel. Technol. 2001; 24: 1323-39.
30. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 1992; 12: 279-98.
31. Yang SY, Huang JW, Shih KY et al. Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid. Nephrol. Dial. Transplant. 2005; 20: 161-6.